SER-109 well-tolerated, reduces recurrent C. difficile infection through 24 weeks

SER-109, an investigational oral microbiome therapeutic, was well-tolerated and durably reduced rates of recurrent Clostridioides difficile infection through 24 weeks, with benefits showing as early as week 2, data show.SER-109 (Seres Therapeutics) is an oral capsule prepared from healthy donor stool containing dormant Firmicute spores that are activated in the lower GI tract. It received orphan drug and breakthrough therapy designations from the FDA in 2015, and appeared to prevent C. difficile infection (CDI) recurrence in a previous phase 1b trial, with 86.7% of patients achieving theRead More